your response should have been Ovarian ""has Not been dropped""
Ruck posted
"One cancer target has been dropped"
this is Wrong
AI Overview
Learn more
As of today, there are currently no approved immune checkpoint inhibitors specifically for ovarian cancer, meaning that no checkpoint-based immunotherapy is considered a standard treatment option for this type of cancer; clinical trials have shown limited efficacy for these drugs in ovarian cancer patients. |
so that tells you the CD4 killer function is suppressed not used like an old gene
moditope effectively turns it on
a double positive
ATB |
so this is your problem Ruck
Scancell does indeed "and its proven" to induce the right t cells for the job
it extremely difficult to improve on that without causing over reactive t cells so you run the risk of auto immune
its proven by trial and in "theory" that its these T cells that you have to activate
a High Avidity Cd8 Th1 and a High Avidity Cd4 helper Th1
but be careful Moditope is in effect a double positive t cell
AI Overview
Learn more
Yes, both CD4 and CD8 T cells originate from the same precursor cell in the thymus, known as a "double positive" T cell, which expresses both CD4 and CD8 markers during early development; essentially, they start off as the same T cell before differentiating into distinct lineages based on further signaling and selection processes within the thymus. |
I believe there were initially three targets for MODI1. We are now down to two - head and neck and renal. I think the third was ovarian. Happy to be corrected if that's not right. |
 looks like High Avidity are also capable of releasing 3 signals to other T cells
Since both human and murine virus-specific T cells with increased peptide sensitivity and virus control secrete multiple pro-inflammatory cytokines,7,10 we applied a similar functional analysis to our CTL clones, comparing 10 cytokines and chemokines. Likewise, we found that CD8+ CTLs with enhanced peptide sensitivity and high capacity for tumor recognition secreted a triplet of CD4-associated type 1 helper (Th1)-cytokines, including IFNγ, interleukin-2 (IL-2) and tumor necrosis factor α (TNFα), whereas lower avidity CTLs failed to produce these three cytokines simultaneously (Fig. 1B). These results extended the findings made with virus-specific CTLs to tumor-specific CD8+ T cells, by showing that high peptide sensitivity correlates with Th1-polycytokine production and a good control of tumor cells in vitro. Crucially, the TCR sequence of a high-avidity CTL clone transferred high antigen sensitivity, enhanced tumor recognition and capacity for Th1-polycytokine secretion to recipient lymphocytes, which represent the therapeutic form for clinical application. |
there is a limit too how far you can push the t cell reactivity
because you are border line auto immune disease
so don't think its easy, and for the competition to improve on Immunobody a tough ask |
AI Overview
Learn more
The "most potent" T cell avidity refers to the highest level of binding strength between a T cell receptor (TCR) and its cognate antigen-MHC complex, signifying a very strong interaction that leads to a robust immune response; essentially, a T cell with the highest avidity is the most likely to become activated and effectively target the antigen-presenting cell. |
I have questioned your post why not answer |
and just to remind you Ruck
Ctl-4 and Pd-1 checkpoints will not work without t cells apart from making you sick
and believe it or not ... its the t cells that cause Pd-1 activation in the cancer
Yes, PD-1 (programmed cell death protein 1) is considered a reaction to inflammation, as its expression on T cells increases during inflammatory conditions, acting as an immune checkpoint to dampen the immune response and prevent excessive inflammation or tissue damage; essentially, it functions as a "brake" on the immune system when inflammation is present.
Lindy knew this back in the mouse days ... it was not new in 2012 .. just not approved
if your T cells "Don't work" = NO inflammation |
Inan, "the T cells are facts ..."So is 9.25p"another ?1000 at 9.32"Confirms the above, otherwise insignificant |
i tell you what else is fact
another £1000 at 9.32 |
the T cells are facts ...
they do actually exist and your blood is packed with them
its called a naive T cell repertoire |
which target has been dropped ? |
Inan, A nice upbeat post highlighting the scientific theory. Reminds me of the initial excitement surrounding the Moditope discovery, the fantastic results seen in laboratory mice and the assertion that tumours just "melt away". This, coupled with the claim Moditope would work standalone saw the share price go from 15p to 60p over a three month period. That was over 12 years ago. The reality has been a little different. In actual human trials, tumours haven't "melted away" and it has been discovered that Moditope will need help from checkpoint inhibitors. One cancer target has been dropped from the trial. These factors has seen the share drop to a 12 month low just over 9p. So by all means, keep spouting the theory meanwhile the market will assess the facts. |
The funding backdrop for any company that develops believe it or not even property developers unless you have cash flow the regular banks are out of the game. I don't have to worry now about banks like i did 20 years ago but life was a whole lot different then, but as you get older you get used to the hassle, however "humility" is tricky subject, many take my info as if its my job ! if you try and predict, it becomes a weapon, then time scales change, who would have thought enolase would take 2 years to crack or covid coming along etc .. however time was not lost because Scancell developed the glymab, Homocitrulline and discovered Avidmab, so the share price may be reflective of delay, but that has also broken the link to the reality of the science. This is what many folks have not considered. From a commercial standpoint what has been spent and raised is chicken feed but look what scancell has achieved with that ..
Take a Look at Inovio retained loss ... a DNA vaccine developer, its frightening and they still have little to show.
How much has GSK written off
etc
and as i have explained today its not about the quantity of t cells the vaccine produces, or the number of targets you attempt to go after
its the elusive reactive t cells ... that your own body "deletes" High Avidity
add with checkpoint support ........... synergy
Moditope different ball game because that is targeting a symptom of the cancer itself Autophagy
But the function of the T cell is critical ...
so once you know you have these Critical t cells
you have effectively proven the product
and the best part they are platforms ..
because reactive t cells will kill anything
they do not care about precancer, cancer, virus, bacteria or what you want to call the vaccine |
Inanaco I suspect your posts do have engagement actually. Look while we don't see eye to eye on everything I do respects your insights, as I suspect do many others. Where you maybe come up short is on the humility side but I suspect you already know that. Personally, I always get something from your posts - though I don't necessarily have as bullish a view as you clearly do. I've always felt scancell offers one of the most asymmetric return profiles I have ever seen but I have always felt it was years away. That was around 14/15/16 when Team Ramp was in full effect (big news tomorrow). Now we are years later - I must fess up that I was very wrong with timing and underestimated how difficult the funding backdrop is in the UK for biotech firms. Against that backdrop I must mull that potentially not only was my timing poor but my entire investment thesis. |
If you break the link 'risk'...the share will fly ...
That's not the issue inane.
Stock trajectory is not about the 'product risk'
Has not the 'risk' to a scancell product decreased over the last 3 years ?
Yet the share price has lost 2/3.
So apply intellectual honesty. Your premise is WRONG.
Little point me telling you what drives price because you wouldn't understand.
.
But as for product risk....that is always there and will be for quite a long time yet. |
if you can break the link . "risk" the share will fly
its that simple
its also not helpful that woodford took so many for a ride in this sector |
I dont think its disabled Tf ...
the issue is lack of any clear definitive posts by others on just how good scancell data really is
these huge posts i have done ... hardly get any recognition apart from Knowlesi of all people
and Marcus "Gets it"
so do tell how to convince people that the "proven" is actually proven when in there head it isn't
Lindy we have great t cells ... we are nearly there !
so even you think Risk why ? |
What sparked his recent Hols to thailand ... not only that to Paknampran !!
so funny |
Register for streaming realtime charts, analysis tools, and prices.
Hot Features
Premium
